bioMérieux

Stocks

BIM

FR0013280286

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-08 am EDT			5-day change	1st Jan Change
72.35 ^EUR	-0.69%		+1.19%	-34.41%

Jun. 04	What Bundibugyo Ebola vaccines and treatments are under development	RE
Jun. 01	BioMérieux in the red following UBS downgrade

Transcript : BioMérieux S.A., H1 2023 Earnings Call, Sep 01, 2023

Published on 08/31/2023

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and welcome to the bioMérieux H1 2023 Financial Performance Conference Call. Today's conference is being recorded. At this time, I would like

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about bioMérieux

Jun. 04	What Bundibugyo Ebola vaccines and treatments are under development	RE
Jun. 01	BioMérieux in the red following UBS downgrade
Jun. 01	UBS Downgrades bioMérieux to Neutral, Cuts PT	MT
Jun. 01	UBS downgrades bioMérieux to neutral, shares retreat
Jun. 01	French Analyst Ratings: UBS downgrades Biomerieux, Soitec remains in favor
May. 29	Biomérieux Invests EUR 250 Million to Build New Manufacturing Facility in France	CI
May. 29	BioMérieux to build new production facility in Isère
May. 29	BioMérieux to Spend EUR250 Million on New French Manufacturing Facility	MT
May. 27	Minaris Advanced Therapies, LLC Expands Rapid Mycoplasma Detection Services With bioMérieux's BIOFIRE Platform To Reduce Turnaround Time For Release And In-Process Testing	CI
May. 19	Test shortages slow fight against Ebola in Congo, WHO official says	RE
May. 07	The Rally Spreads
May. 06	L'Institut Merieux: bought an extra 1% in Biomérieux, bringing its total stake in company to around 60%	RE
Apr. 24	Deutsche Bank Downgrades bioMérieux to Hold, Cuts PT	MT
Apr. 23	BioMerieux: Disappointing Q1 and lower guidance undermine investor confidence
Apr. 23	BioMérieux S.A., Q1 2026 Sales/ Trading Statement Call, Apr 23, 2026